Clinical Trial Update: Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing longitudinal PET imaging [18F]PI-2620 in cognitively normal individuals, mild cognitive impairment, and Alzheimer's dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• [18F]PI-2620 (PI-2620)

Snippet

Sponsor: Jae Seung Kim | Conditions: Cognitively Normal, Mild Cognitive Impairment | Phase 2 | Status: COMPLETED